A carregar...
Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses
Few cancer drugs or their indications achieved survival benefit in subsequent trials during postmarket period after approval based on surrogate endpoints. This causes a concern of using surrogate endpoints instead of overall survival (OS) as the primary endpoint for trial design, implementation and...
Na minha lista:
| Publicado no: | Ann Transl Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6603357/ https://ncbi.nlm.nih.gov/pubmed/31317014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.04.72 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|